Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Osimertinib versus afatinib in patients with T790M-positive, non-small-cell lung cancer and multiple central nervous system metastases after failure of initial EGFR-TKI treatment

Abstract Background The purpose of this study was to compare the efficacy of osimertinib (OSI) versus afatinib (AFA) in patients with T790M-positive, non-small-cell lung cancer (NSCLC) and multiple central nervous system (CNS) metastases after failure of initial epidermal growth factor receptor tyro...

Full description

Bibliographic Details
Main Authors: Yang Yang, Qilong Liu, Lei Cao, Wei Sun, Xiaowei Gu, Bin Liu, Na Xiao, Fei Teng, Xiaoli Li, Meiji Chen, Weiguang Yu, Huanyi Lin, Guixing Xu
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Pulmonary Medicine
Subjects:
Osimertinib
Afatinib
Non-small-cell lung cancer
Central nervous system
Metastases
Survival
Online Access:https://doi.org/10.1186/s12890-021-01539-x

Internet

https://doi.org/10.1186/s12890-021-01539-x

Similar Items